The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Non-invasive Parenteral Screening Instruments Market Research Report 2024
Synopsis
Non-invasive Parenteral Screening is a nascent genetic process of examining a fetal cell free DNA present in the mothers blood serum for detecting common fetal aneuploidies. Its main objective is early detection of genetic disorders such as trisomy 21 (Down syndrome), trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome), and monosomy X (Turner syndrome). It can also detect the blood group and rhesus actor of the fetus. Some of the NIPTs currently available in the global market are MaterniT21 PLUS, Harmony, Panorama, NIFTY, PrenaTest, BambniTest, and others.
The global Non-invasive Parenteral Screening Instruments market was valued at US$ 3812 million in 2023 and is anticipated to reach US$ 7241.6 million by 2030, witnessing a CAGR of 9.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-invasive Parenteral Screening Instruments, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-invasive Parenteral Screening Instruments.
Report Scope
The Non-invasive Parenteral Screening Instruments market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-invasive Parenteral Screening Instruments market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-invasive Parenteral Screening Instruments companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GE Healthcare
Philips
Illumina
Thermo Fisher Scientific
Roche
PacBio
Perkinelmer
Qiagen
Agilent Technologies
BGI Group
Segment by Type
Ultrasound Devices
Next-Generation Sequencing Systems
Polymerase Chain Reaction Instruments
Microarrays
Others
Segment by Application
Diagnostic Laboratories
Hospitals
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-invasive Parenteral Screening Instruments companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Non-invasive Parenteral Screening is a nascent genetic process of examining a fetal cell free DNA present in the mothers blood serum for detecting common fetal aneuploidies. Its main objective is early detection of genetic disorders such as trisomy 21 (Down syndrome), trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome), and monosomy X (Turner syndrome). It can also detect the blood group and rhesus actor of the fetus. Some of the NIPTs currently available in the global market are MaterniT21 PLUS, Harmony, Panorama, NIFTY, PrenaTest, BambniTest, and others.
The global Non-invasive Parenteral Screening Instruments market was valued at US$ 3812 million in 2023 and is anticipated to reach US$ 7241.6 million by 2030, witnessing a CAGR of 9.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-invasive Parenteral Screening Instruments, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-invasive Parenteral Screening Instruments.
Report Scope
The Non-invasive Parenteral Screening Instruments market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-invasive Parenteral Screening Instruments market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-invasive Parenteral Screening Instruments companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GE Healthcare
Philips
Illumina
Thermo Fisher Scientific
Roche
PacBio
Perkinelmer
Qiagen
Agilent Technologies
BGI Group
Segment by Type
Ultrasound Devices
Next-Generation Sequencing Systems
Polymerase Chain Reaction Instruments
Microarrays
Others
Segment by Application
Diagnostic Laboratories
Hospitals
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-invasive Parenteral Screening Instruments companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-invasive Parenteral Screening Instruments Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Ultrasound Devices
1.2.3 Next-Generation Sequencing Systems
1.2.4 Polymerase Chain Reaction Instruments
1.2.5 Microarrays
1.2.6 Others
1.3 Market by Application
1.3.1 Global Non-invasive Parenteral Screening Instruments Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Diagnostic Laboratories
1.3.3 Hospitals
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-invasive Parenteral Screening Instruments Market Perspective (2019-2030)
2.2 Non-invasive Parenteral Screening Instruments Growth Trends by Region
2.2.1 Global Non-invasive Parenteral Screening Instruments Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-invasive Parenteral Screening Instruments Historic Market Size by Region (2019-2024)
2.2.3 Non-invasive Parenteral Screening Instruments Forecasted Market Size by Region (2025-2030)
2.3 Non-invasive Parenteral Screening Instruments Market Dynamics
2.3.1 Non-invasive Parenteral Screening Instruments Industry Trends
2.3.2 Non-invasive Parenteral Screening Instruments Market Drivers
2.3.3 Non-invasive Parenteral Screening Instruments Market Challenges
2.3.4 Non-invasive Parenteral Screening Instruments Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-invasive Parenteral Screening Instruments Players by Revenue
3.1.1 Global Top Non-invasive Parenteral Screening Instruments Players by Revenue (2019-2024)
3.1.2 Global Non-invasive Parenteral Screening Instruments Revenue Market Share by Players (2019-2024)
3.2 Global Non-invasive Parenteral Screening Instruments Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-invasive Parenteral Screening Instruments Revenue
3.4 Global Non-invasive Parenteral Screening Instruments Market Concentration Ratio
3.4.1 Global Non-invasive Parenteral Screening Instruments Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-invasive Parenteral Screening Instruments Revenue in 2023
3.5 Non-invasive Parenteral Screening Instruments Key Players Head office and Area Served
3.6 Key Players Non-invasive Parenteral Screening Instruments Product Solution and Service
3.7 Date of Enter into Non-invasive Parenteral Screening Instruments Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-invasive Parenteral Screening Instruments Breakdown Data by Type
4.1 Global Non-invasive Parenteral Screening Instruments Historic Market Size by Type (2019-2024)
4.2 Global Non-invasive Parenteral Screening Instruments Forecasted Market Size by Type (2025-2030)
5 Non-invasive Parenteral Screening Instruments Breakdown Data by Application
5.1 Global Non-invasive Parenteral Screening Instruments Historic Market Size by Application (2019-2024)
5.2 Global Non-invasive Parenteral Screening Instruments Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-invasive Parenteral Screening Instruments Market Size (2019-2030)
6.2 North America Non-invasive Parenteral Screening Instruments Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Non-invasive Parenteral Screening Instruments Market Size by Country (2019-2024)
6.4 North America Non-invasive Parenteral Screening Instruments Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-invasive Parenteral Screening Instruments Market Size (2019-2030)
7.2 Europe Non-invasive Parenteral Screening Instruments Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Non-invasive Parenteral Screening Instruments Market Size by Country (2019-2024)
7.4 Europe Non-invasive Parenteral Screening Instruments Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-invasive Parenteral Screening Instruments Market Size (2019-2030)
8.2 Asia-Pacific Non-invasive Parenteral Screening Instruments Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Non-invasive Parenteral Screening Instruments Market Size by Region (2019-2024)
8.4 Asia-Pacific Non-invasive Parenteral Screening Instruments Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-invasive Parenteral Screening Instruments Market Size (2019-2030)
9.2 Latin America Non-invasive Parenteral Screening Instruments Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Non-invasive Parenteral Screening Instruments Market Size by Country (2019-2024)
9.4 Latin America Non-invasive Parenteral Screening Instruments Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-invasive Parenteral Screening Instruments Market Size (2019-2030)
10.2 Middle East & Africa Non-invasive Parenteral Screening Instruments Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Non-invasive Parenteral Screening Instruments Market Size by Country (2019-2024)
10.4 Middle East & Africa Non-invasive Parenteral Screening Instruments Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GE Healthcare
11.1.1 GE Healthcare Company Detail
11.1.2 GE Healthcare Business Overview
11.1.3 GE Healthcare Non-invasive Parenteral Screening Instruments Introduction
11.1.4 GE Healthcare Revenue in Non-invasive Parenteral Screening Instruments Business (2019-2024)
11.1.5 GE Healthcare Recent Development
11.2 Philips
11.2.1 Philips Company Detail
11.2.2 Philips Business Overview
11.2.3 Philips Non-invasive Parenteral Screening Instruments Introduction
11.2.4 Philips Revenue in Non-invasive Parenteral Screening Instruments Business (2019-2024)
11.2.5 Philips Recent Development
11.3 Illumina
11.3.1 Illumina Company Detail
11.3.2 Illumina Business Overview
11.3.3 Illumina Non-invasive Parenteral Screening Instruments Introduction
11.3.4 Illumina Revenue in Non-invasive Parenteral Screening Instruments Business (2019-2024)
11.3.5 Illumina Recent Development
11.4 Thermo Fisher Scientific
11.4.1 Thermo Fisher Scientific Company Detail
11.4.2 Thermo Fisher Scientific Business Overview
11.4.3 Thermo Fisher Scientific Non-invasive Parenteral Screening Instruments Introduction
11.4.4 Thermo Fisher Scientific Revenue in Non-invasive Parenteral Screening Instruments Business (2019-2024)
11.4.5 Thermo Fisher Scientific Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Non-invasive Parenteral Screening Instruments Introduction
11.5.4 Roche Revenue in Non-invasive Parenteral Screening Instruments Business (2019-2024)
11.5.5 Roche Recent Development
11.6 PacBio
11.6.1 PacBio Company Detail
11.6.2 PacBio Business Overview
11.6.3 PacBio Non-invasive Parenteral Screening Instruments Introduction
11.6.4 PacBio Revenue in Non-invasive Parenteral Screening Instruments Business (2019-2024)
11.6.5 PacBio Recent Development
11.7 Perkinelmer
11.7.1 Perkinelmer Company Detail
11.7.2 Perkinelmer Business Overview
11.7.3 Perkinelmer Non-invasive Parenteral Screening Instruments Introduction
11.7.4 Perkinelmer Revenue in Non-invasive Parenteral Screening Instruments Business (2019-2024)
11.7.5 Perkinelmer Recent Development
11.8 Qiagen
11.8.1 Qiagen Company Detail
11.8.2 Qiagen Business Overview
11.8.3 Qiagen Non-invasive Parenteral Screening Instruments Introduction
11.8.4 Qiagen Revenue in Non-invasive Parenteral Screening Instruments Business (2019-2024)
11.8.5 Qiagen Recent Development
11.9 Agilent Technologies
11.9.1 Agilent Technologies Company Detail
11.9.2 Agilent Technologies Business Overview
11.9.3 Agilent Technologies Non-invasive Parenteral Screening Instruments Introduction
11.9.4 Agilent Technologies Revenue in Non-invasive Parenteral Screening Instruments Business (2019-2024)
11.9.5 Agilent Technologies Recent Development
11.10 BGI Group
11.10.1 BGI Group Company Detail
11.10.2 BGI Group Business Overview
11.10.3 BGI Group Non-invasive Parenteral Screening Instruments Introduction
11.10.4 BGI Group Revenue in Non-invasive Parenteral Screening Instruments Business (2019-2024)
11.10.5 BGI Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
